Abraham NG+ editorial board - Health Sciences Library - New York ...
Abraham NG+ editorial board - Health Sciences Library - New York ...
Abraham NG+ editorial board - Health Sciences Library - New York ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Chen LJ, Tam PO, Tham CC, Liang XY, Chiang SW, Canlas O, Ritch R+, Rhee DJ, Pang CP.<br />
Evaluation of SPARC as a candidate gene of juvenile-onset primary open-angle glaucoma<br />
by mutation and copy number analyses. Mol Vis 2010 Oct;16:2016-25.<br />
Dept: Ophthalmology PMID: 21042566<br />
Chen MJ, Yang PY, Ye YZ, Hu DN+, Chen MF. Arsenic trioxide induces apoptosis in uveal<br />
melanoma cells through the mitochondrial pathway. Am J Chin Med 2010;38(6):1131-42.<br />
Dept: Ophthalmology PMID: 21061466 DOI: 10.1142/S0192415X10008524<br />
Chen X, Wang J, Shen H, Lu J, Li C, Hu DN+, da Dong X, Yan D, Tu L. Epigenetics, microRNAs,<br />
and carcinogenesis: Functional role of microRNA-137 in uveal melanoma. Invest<br />
Ophthalmol Vis Sci 2011 Mar;52(3):1193-9.<br />
Dept: Ophthalmology DOI: 10.1167/iovs.10-5272<br />
Chen YJ, Santos M, Quilley J+. Treatment of diabetic rats with a peroxynitrite decomposition<br />
catalyst prevents induction of renal COX-2. Am J Physiol Heart Circ Physiol 2011<br />
Mar;300(3):H1125-32.<br />
Dept: Pharamcology PMID: 21239635 DOI: 10.1152/ajpheart.00768.2010<br />
Cheng-Lai A; Frishman WH+. Appendix 1: Pharmacokinetic properties of approved<br />
cardiovascular drugs. In: Frishman WH+; Sica DA, editors. Cardiovascular<br />
pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext; 2011. pp. 633-51.<br />
Dept: Medicine<br />
Cheng-Lai A; Frishman WH+. Appendix 2: Therapeutic use of available cardiovascular drugs. In:<br />
Frishman WH+; Sica DA, editors. Cardiovascular pharmacotherapeutics. 3rd ed.<br />
Minneapolis, MN: Cardiotext; 2011. pp. 653-719.<br />
Dept: Medicine<br />
Cheng-Lai A; Frishman WH+. Appendix 3: Guide to cardiovascular drug use in pregnancy and<br />
with nursing. In: Frishman WH+; Sica DA, editors. Cardiovascular pharmacotherapeutics.<br />
3rd ed. Minneapolis, MN: Cardiotext; 2011. pp. 721-7.<br />
Dept: Medicine<br />
Cheng-Lai A; Frishman WH+. Appendix 4: Dosing recommendations of cardiovascular drugs in<br />
patients with hepatic disease and/or congestive heart failure. In: Frishman WH+; Sica DA,<br />
editors. Cardiovascular pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext; 2011.<br />
pp. 729-34.<br />
Dept: Medicine<br />
Cheng-Lai A; Frishman WH+. Appendix 5: Dose adjustment in patients with renal insufficiency.<br />
In: Frishman WH+; Sica DA, editors. Cardiovascular pharmacotherapeutics. 3rd ed.<br />
Minneapolis, MN: Cardiotext; 2011. pp. 735-41.<br />
Dept: Medicine<br />
Cheng-Lai A; Frishman WH+. Appendix 6: Selected cardiovascular medications and gender<br />
issues. In: Frishman WH+; Sica DA, editors. Cardiovascular pharmacotherapeutics. 3rd ed.<br />
Minneapolis, MN: Cardiotext; 2011. pp. 743-4.<br />
Dept: Medicine<br />
Cheng-Lai A; Frishman WH+. Appendix 7: Pharmacokinetic changes, route of elimination, and<br />
dosage adjustment of selected cardiovascular drugs in the elderly. In: Frishman WH+; Sica<br />
DA, editors. Cardiovascular pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext;<br />
+ indicates NYMC faculty 18
Change language